Tenoxicam loaded hyalcubosomes for osteoarthritis
| Autor: | Mona K. Younis, Rasha M. Allam, Yara E. Elakkad, Amany F. Mohsen, Islam A. Khalil |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Sodium hyaluronate
Pharmaceutical Science Human skin 02 engineering and technology Osteoarthritis Poloxamer Administration Cutaneous 030226 pharmacology & pharmacy Clinical study 03 medical and health sciences chemistry.chemical_compound Piroxicam 0302 clinical medicine Tenoxicam medicine Animals Humans Particle Size Chemistry Vesicle Permeation 021001 nanoscience & nanotechnology medicine.disease Rats 0210 nano-technology Biomedical engineering medicine.drug |
| Zdroj: | International journal of pharmaceutics. 601 |
| ISSN: | 1873-3476 |
| Popis: | The main aim is to develop transcutaneous tenoxicam (TNX) loaded vesicles to control osteoarthritis (OA) without common side effects. Different vesicles were prepared by the emulsification technique, where poloxamer and glyceryl monooleate used for cubosomes. Then, hyalcubosomes were prepared by adding sodium hyaluronate to cubosomes components. Different characterization techniques were used. The selected formulations were tested using an ex-vivo permeation study to evaluate the ability to penetrate and retained in skin layers. Also, in-vitro cell studies using human skin fibroblasts were evaluated the safety of the formulation. The anti-inflammatory efficiency was tested using an in-vivo carrageenan-induced rat paw edema model. Finally, the efficiency to control OA symptoms was tested on three patients with a medical history of knee OA. Results confirmed the successful development of spherical cubosomes with particle size250 nm, -14.5 mV, high entrapment efficiency percentage (90%). Moreover, the addition of sodium hyaluronate to selected cubosomes improved viscosity and spreadability. Permeation study confirmed drug penetration and deposition. Cell studies proved the safety of the selected formulation. The animal model showed high anti-inflammatory activity. Finally, the preliminary clinical study demonstrates the potential efficacy and safety of the formulation in controlling OA symptoms over 8 weeks of therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect